June 27, 2024 10:42 AM EDTUpdated 04:23 PM

AbbVie buys Third Rock's Celsius for $250M to expand IBD pipeline

Kyle LaHucik

Senior Reporter

As AbbVie continues to tout its next generation of immunology drugs behind Humira, it’s buying an early-stage startup to boost its longer-term prospects in inflammatory …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AbbVie buys Third Rock's Celsius for $250M to expand IBD pipeline

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Why the Supreme Court's overrule of Chevron has major implications for the FDA

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Inside BARDA's multibillion-dollar effort to fund long-shot biotechs for Covid

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Immunology biotech Alumis secures $250M in shrunken IPO

Ab­b­Vie buys Third Rock­'s Cel­sius for $250M to ex­pand IBD pipeline

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

more like this

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

Sci­en­tists un­veil new way to make large changes to genes, and no CRISPR is re­quired

In­side BAR­DA's multi­bil­lion-dol­lar ef­fort to fund long-shot biotechs for Covid

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

Im­munol­o­gy biotech Alu­mis se­cures $250M in shrunk­en IPO

AbbVie buys Third Rock's Celsius for $250M to expand IBD pipeline

Why the Supreme Court's overrule of Chevron has major implications for the FDA

J&J details Phase 3 success of autoimmune disease drug, touting broader range than argenx’s Vyvgart

Scientists unveil new way to make large changes to genes, and no CRISPR is required

Inside BARDA's multibillion-dollar effort to fund long-shot biotechs for Covid

FDA rejects Rocket Pharma’s ultra-rare immune disease gene therapy over manufacturing

Immunology biotech Alumis secures $250M in shrunken IPO